Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
November 08, 2023 21:20 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the...
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
November 08, 2023 16:10 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that...
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
November 06, 2023 16:05 ET
|
Myriad Genetics, Inc.
Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year...
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
November 01, 2023 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief...
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
October 31, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on...
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
October 26, 2023 08:00 ET
|
Myriad Genetics, Inc.
Partnership covers development of lab-developed and distributable kit-based companion diagnostic testsCombined strengths in assay development, clinical testing, and regulatory approvals offers pharma...
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
September 28, 2023 07:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey...
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
September 19, 2023 09:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic...
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
September 19, 2023 07:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social...
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...